Comments
Glenmark Pharmaceuticals on Friday said it has received final approval from the US health regulator for its generic version of BenzaClin gel used in the treatment of acne.
The approval granted to Glenmark Pharmaceuticals Inc, USA (Glenmark) by the United States Food & Drug Administration (USFDA) is for Clindamycin and Benzoyl Peroxide Gel, 1 per cent|5 per cent, a generic version of BenzaClin1 Gel, 1 per cent/ 5 per cent, of Valeant Bermuda, the company said in a statement.
Citing IQVIATM sales data, Glenmark said BenzaClin Gel, 1 per cent/ 5 per cent had sales of $99.4 million in the 12-month period ended January 2019.
Glenmark’s current portfolio consists of 151 products authorised for distribution in the US with 53 ANDAs (abbreviated new drug applications) pending approval with the USFDA.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.